FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) Delaware 13-3326724 (State or other j ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 1 ...

RadNet, Inc. (NASDAQ:RDNT) Q4 2022 Earnings Conference Call February 28, 2023 10:30 AM ET Company Participants Mark Stolper - EVP and CFO Howard Berger - CEO Conference Call Participants Brian Tanquilut - Jefferies John Ransom - Raymond James Mitra Ramgopal - Sidoti & Company Operator Greetings, and welcome to the RadNet Inc. Fourth Quarter 2022 Financial Results Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) Delaware 13-3326724 (State or oth ...

Financial Data and Key Metrics Changes - For Q3 2022, RadNet reported revenue of $349.1 million from its Imaging Centers segment, a 5.1% increase from the previous year, while adjusted EBITDA decreased by 8.5% to $50.2 million [29][30] - The overall revenue, including the AI segment, was $350 million, reflecting a 5.2% increase from $332.7 million in Q3 2021 [30] - Net income for Q3 2022 was $668,000, down from $16.2 million in Q3 2021, with diluted net income per share decreasing from $0.30 to $0.01 [31] Business Line Data and Key Metrics Changes - Revenue from Imaging Centers increased by 5.2%, with aggregate procedural volume up by 5.7% and same-store procedure volumes rising by 3.9% [8] - MRI volume increased by 10.8%, CT volume by 9.6%, and PET/CT volume by 11.5% compared to the previous year [35] - Total procedures performed in Q3 2022 reached 2,311,448, with routine imaging exams accounting for 75.4% of the volume [36] Market Data and Key Metrics Changes - The demand for imaging services is strong, with increasing patient volumes across all regional markets, particularly noted in October as the strongest revenue month of the year [12] - Staffing shortages have impacted the ability to meet demand, but recent improvements in filling open positions have been observed [11] Company Strategy and Development Direction - The company is developing 15 new facilities, with three already open and eight expected to generate revenue by the end of Q2 2023 [14] - Expansion through joint ventures with hospitals and health systems is a key strategy, with 33% of facilities now in partnerships [15] - The acquisition of Heart&Lung Health, a teleradiology network, is part of a strategy to enhance cancer screening services [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for Q4 2022 and 2023, citing strong demand and improved staffing conditions [12][62] - The company anticipates that higher labor costs will persist but is implementing measures to manage these costs effectively [63][68] - The healthcare sector is expected to remain resilient during potential recessionary conditions, with a continued shift towards outpatient services [75] Other Important Information - Cash balance at the end of Q3 was over $95 million, with a record low DSO of 37 days [24][40] - Revised financial guidance for 2022 includes unchanged revenue expectations and adjusted EBITDA guidance of $203 million to $208 million [42] Q&A Session Summary Question: Thoughts on Q3 results and cost challenges - Management acknowledged labor challenges impacting both revenue and costs, but noted improvements in staffing and confidence moving into Q4 [57][60] Question: Outlook for 2023 and EBITDA growth - Management highlighted initiatives to expand hospital partnerships and new centers, projecting significant revenue growth from these efforts [65][66] Question: Details on the Enhanced Breast Cancer Detection program - The pilot program in Delaware has received positive feedback, with a significant percentage of patients enrolling [69][70] Question: Impact of potential Alzheimer's drugs on imaging - Management is already conducting studies related to Alzheimer's and expects increased demand for imaging services if new drugs are approved [71][72] Question: Resilience of the business in a recession - Management believes healthcare is generally insulated from recessionary impacts and expects continued volume growth due to demographic trends [75][78] Question: Expansion in Arizona and growth opportunities - Management confirmed confidence in the Arizona market and plans for further expansion in collaboration with Dignity Health [79][80] Question: Prioritization of growth opportunities - All growth avenues, including JVs, M&A, and AI investments, are considered priorities, with a focus on teleradiology as a future growth area [81][83]

RadNet, Inc. (NASDAQ:RDNT) Q2 2022 Earnings Conference Call August 9, 2022 10:30 AM ET Company Participants Mark Stolper - EVP and CFO Howard Berger - CEO Conference Call Participants Brian Tanquilut - Jefferies Sarah James - Barclays Mitra Ramgopal - Sidoti Operator Good day, ladies and gentlemen, and welcome to the RadNet, Inc. Second Quarter 2022 Financial Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. Mark Stolper, Executive V ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33307 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or RadNet, Inc. (Exact name of registrant as specified in its charter) Delaware 13-3326724 (State or other ju ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) Delaware 13-3326724 (State or other j ...

RadNet, Inc. (NASDAQ:RDNT) Q1 2022 Earnings Conference Call May 9, 2022 10:30 AM ET Company Participants Mark Stolper - Executive Vice President and Chief Financial Officer Howard Berger - Chief Executive Officer Conference Call Participants Brian Tanquilut - Jefferies Mitra Ramgopal - Sidoti Operator Good day and welcome to the RadNet, Inc. First Quarter 2022 Financial Results Conference Call. Today’s conference is being recorded. At this time, I’d like to turn the conference over to Mr. Mark Stolper, Exec ...

Leading Radiology Forward Mark Stolper Chief Financial Officer March 2022 NASDAQ: RDNT Safe Harbor This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning RadNet's ability to continue to grow the business by generating patient referrals and contracts with radiology practices, integrate acquired businesses, recruit and retain technologists, and receive third-party reimbursement for diagnostic im ...